MedImmune To Release Phase III Data By Year-End For Synagis Follow-On
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune is on track to launch the newest member of its respiratory syncytial virus therapy franchise for the 2008–2009 respiratory virus season.
You may also be interested in...
MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23
While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.
MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23
While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.
Refrigerator-Stable FluMist Submitted For Young Children
MedImmune submitted a supplemental BLA seeking use of refrigerator-stable intranasal flu vaccine FluMist to inoculate children ages 12 months to 59 months, the company announced July 31